Panacea Biotec Ltd. Reports Share Dematerialization Data for February 2026
Panacea Biotec Limited reported share dematerialization data for February 2026. As of February 28, 2026, a total of 6,11,04,526 shares were dematerialized, comprising 5,34,51,058 from NSDL and 76,53,468 from CDSL. This filing is in compliance with SEBI regulations.
This is a routine compliance filing related to share dematerialization, which is a standard operational process and is unlikely to have a significant impact on the company's stock price or business operations.
The announcement is a routine regulatory filing regarding share dematerialization data and does not contain any specific financial performance indicators or strategic business updates that would influence market sentiment.
Panacea Biotec Limited has submitted its share dematerialization details for the month of February 2026, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The company informed the stock exchanges about the securities dematerialized during February 2026, as per CDSL's instructions for Issuers and RTAs. The data of shares dematerialized has been enclosed as Annexure - 1.
As of February 28, 2026, the total number of shares dematerialized were 5,34,51,058 with NSDL and 76,53,468 with CDSL, bringing the total to 6,11,04,526 shares. A certificate from the company's Registrar and Share Transfer Agent (RTA), Skyline Financial Services Pvt. Ltd., confirming these dematerialization figures as of February 28, 2026, has also been enclosed as Annexure - 2.
The announcement was made on March 06, 2026.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under shareholding pattern. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.